-
Mashup Score: 0Prostate Cancer Cell Metabolism Dictates Differentiation and Therapy Response - Andrew Goldstein - 51 minute(s) ago
Andrea Miyahira hosts Andrew Goldstein to discuss his group’s research on prostate cancer, published in Nature Cell Biology. Dr. Goldstein, along with his team, including grad students Jenna Giafaglione and Preston Crowell, explores the metabolic processes influencing prostate cancer’s response to anti-androgen treatment. Their study reveals that basal and luminal cells in the prostate have…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Predictive Markers in Prostate Cancer: Insights from the VISION Trial on Lutetium-PSMA-617 - Oliver Sartor - 2 hour(s) ago
Evan Yu and Oliver Sartor discuss the VISION trial’s exploration of predictive and prognostic markers in the treatment of prostate cancer with Lutetium-PSMA-617. Sartor clarifies the distinction between predictive and prognostic markers, emphasizing the trial’s focus on baseline markers and their association with treatment outcomes. The conversation highlights the importance of PSMA PET scans in…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2SPECT Imaging Response with PSMA Radionuclide Therapy "Presentation" - Louise Emmett - 4 hour(s) ago
At the 2024 UCSF-UCLA PSMA Conference, Louise Emmett emphasizes the importance of SPECT imaging in assessing early and interim responses to Lutetium PSMA therapy in prostate cancer, challenging the adequacy of traditional biomarkers like PSA and RECIST. Dr. Emmett discusses a nuanced approach to treatment personalization, suggesting that integrating SPECT imaging with other biomarkers could…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
SPECT imaging response with PSMA radionuclide therapy. @drlouiseemmett presents a nuanced approach to treatment personalization, suggesting the integration of SPECT imaging with other biomarkers enhancing the ability to tailor therapy > https://t.co/I4e0g54b4O @PSMAconference https://t.co/fN2E6a1tfc
-
-
Mashup Score: 0Climate Change Perception and Its Impact on Cancer Screening Intent - Beyond the Abstract - 4 hour(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 16
Ashish Kamat welcomes Professor Mark Tyson to discuss the BOND-003 study results on CG0070, cretostimogene grenadenorepvec (creto), for BCG-unresponsive non-muscle invasive bladder cancer. Creto, an oncolytic adenovirus, selectively infects and kills cancer cells while sparing normal tissue and induces antitumor immunity. The phase 3 study showed a 75.7% complete response at any time point, with…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression - Beyond the Abstract - 5 hour(s) ago
Prostate Cancer, Metformin, NKX3.1, NKX3.1 Loss to Suppress Prostate Cancer Progression, NKX3.1 expression, prostate cancer progression, precision intervention in prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 7BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George - 6 hour(s) ago
Zach Klaassen and Daniel George discuss the highlights from ASCO GU 2024 including the BRCAAway trial, a study focusing on the combination of PARP inhibitors and novel hormonal agents for treating metastatic castration-resistant prostate cancer. Dr. George explains the trial’s innovative design, which explored the efficacy of abiraterone and olaparib, both separately and in combination, in…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The #BRCAAway Trial: Where combination treatment improves patient outcomes in #mCRPC. @Daniel_J_George @DukeCancer & @zklaassen_md @GACancerCenter discuss the combination of PARP inhibitors and novel hormonal agents and the importance of genetic testing > https://t.co/Kyuo70BO7V https://t.co/3RkCep8x3V
-
-
Mashup Score: 9Advances in Staging and Personalized Radiation Therapy for High-Risk Localized Prostate Cancer - Leslie Ballas - 6 hour(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Leslie Ballas, MD , Cedars-Sinai Medical Center, Los Angeles, CA Rana McKay, MD , Medical Oncologist, Associate Professor of Medicine, UC San Diego School of Medicine, San Diego, CA Related Content:…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 9The Biological Basis of mCRPC – The Unmet Medical Need for New Targets/Treatments - Dan George - 6 hour(s) ago
In this educational Masterclass program, titled Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC , Dr Daniel George covers the complex landscape of metastatic castration-resistant prostate cancer (mCRPC) treatments. He highlights the importance of recognizing the heterogeneity in mCRPC, influenced by the treatments patients received and the genetic alterations…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The biological basis of #mCRPC - The unmet medical need for new targets/treatments. @Daniel_J_George joins @CaPsurvivorship as part of this educational #MasterClass discussing the importance of recognizing heterogeneity in mCRPC and more > https://t.co/EQGrEEoj7L @LoxoLillyOnc https://t.co/0RcWCs4vBd
-
-
Mashup Score: 0
Upper Tract Urothelial Cancer (UTUC), Circulating tumor DNA (ctDNA), Circulating Tumour DNA in Plasma Is Feasible and May Be a Potential Biomarker, detection of tumor-specific mutations.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
#ProstateCancer cell metabolism dictates differentiation and therapy response. @ASGoldstein6 joins @AndreaMiyahira to discuss his group's findings published in @NatureCellBio and how metabolic processes shape prostate cancer's response to treatment > https://t.co/kVoKogFDO8 https://t.co/CWV9CQ5s2i